Milka Marinova

Dr. Milka Marinova

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PWPhilipp Westhofen
Philipp Westhofen
MWMatthias Watzka
Matthias Watzka
MMMilka Marinova
Milka Marinova
MHMoritz Hass
Moritz Hass
GKGregor Kirfel
Gregor Kirfel
JOJohannes Oldenburg
Johannes Oldenburg
Human vitamin K 2,3-epoxide reductase complex subunit 1-like 1 (VKORC1L1), expressed in HEK 293T cells and localized exclusively to membranes of the endoplasmic reticulum, was found to support both vitamin K 2,3-epoxide reductase (VKOR) and vitamin K reductase enzymatic activities. Michaelis-Menten kinetic parameters for dithiothreitol-driven VKOR activity were: Km (μm) = 4.15 (vitamin K1 epoxide) and 11.24 (vitamin K2 epoxide); Vmax (nmol·mg−1·hr−1) = 2.57 (vitamin K1 epoxide) and 13.46 (vitamin K2 epoxide). Oxidative stress induced by H2O2 applied to cultured cells up-regulated VKORC1L1 expression and VKOR activity. Cell viability under conditions of no induced oxidative stress was increased by the presence of vitamins K1 and K2 but not ubinquinone-10 and was specifically dependent on VKORC1L1 expression. Intracellular reactive oxygen species levels in cells treated with 2,3-dimethoxy-1,4-naphthoquinone were mitigated in a VKORC1L1 expression-dependent manner. Intracellular oxidative damage to membrane intrinsic proteins was inversely dependent on VKORC1L1 expression and the presence of vitamin K1. Taken together, our results suggest that VKORC1L1 is responsible for driving vitamin K-mediated intracellular antioxidation pathways critical to cell survival.

17 April 2018 in Ultraschall in der Medizin - European Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
MMMilka Marinova
Milka Marinova
HHHannah C. Huxold
Hannah C. Huxold
JHJana Henseler
Jana Henseler
MMMartin Mücke
Martin Mücke
RCRupert Conrad
Rupert Conrad
HSHolger Strunk
Holger Strunk
Purpose Pancreatic cancer (PaC) is a life-limiting tumor with a wide range of incapacitating symptoms such as cancer pain in more than 80 % of patients. This prospective interventional study addresses the clinical effectiveness of ultrasound-guided high-intensity focused ultrasound (HIFU) treatment for patients with advanced-stage PaC, including pain perception, tumor size and survival benefit. Materials and Methods 50 patients with late-stage PaC underwent HIFU. Clinical assessment included evaluation of tumor volume by imaging and pain burden (pain severity, pain sensation, interference with daily activities) using the Brief Pain Inventory at baseline and follow-up. Median overall survival, progression-free survival and time to local progression were estimated using Kaplan-Meier analysis. Results In 84 % of patients, significant early relief of cancer-induced abdominal pain was achieved by HIFU independent of metastatic status; it persisted during follow-up. Tumor volume reduction was 37.8 ± 18.1 % after 6 weeks and 57.9 ± 25.9 % after 6 months. 21 % of HIFU-treated patients had local tumor progression with a median time of 14.4 months from intervention. The median overall survival and progression-free survival were 16.2 and 16.9 months from diagnosis and 8.3 and 6.8 months from intervention. Conclusion In patients with advanced pancreatic cancer and otherwise limited treatment options, HIFU resulted in significant early and long-lasting pain relief and tumor size reduction over time independent of metastatic status. Clinical data suggest an additional potential survival benefit. Ziel Das Pankreaskarzinom ist ein lebenslimitierender Tumor mit einer Vielzahl von tumorbedingen Beschwerden wie Tumorschmerzen bei mehr als 80 % der Patienten. Ziel dieser prospektiven Studie ist, die klinische Wirksamkeit des Ultraschall-gesteuerten hoch-intensiven fokussierten Ultraschalls (HIFU) in Bezug auf die Schmerintensität und -empfindung, die Tumorgröße und das Überleben zu evaluieren. Material und Methode Fünfzig Patienten mit fortgeschrittenem Pankreaskarzinom wurden mit HIFU behandelt. Die klinische Evaluation umfasste die Beurteilung des Tumorvolumens durch bildgebende Verfahren sowie der Schmerzbelastung (Schmerzintensität, Schmerzempfindung, Beeinträchtigung der täglichen Aktivitäten) anhand des Brief-pain-inventory-Fragebogens initial und im Verlauf. Das mediane Gesamtüberleben, das progressionsfreie Überleben und die Zeit bis zum lokalen Progress wurden mit der Kaplan-Meier-Analyse evaluiert. Ergebnisse Nach HIFU wurde bei 84 % der Patienten eine signifikante frühzeitige Reduktion von tumorinduzierten Bauchschmerzen unabhängig vom Metastasierungsstatus erreicht; dieser Effekt blieb im Verlauf erhalten. Die Tumorvolumenreduktion betrug 37,8 ± 18,1 % nach 6 Wochen und 57,9 ± 25,9 % nach 6 Monaten. 21 % der HIFU-behandelten Patienten hatten einen lokalen Tumorprogress mit einer medianen Zeit von 14,4 Monaten nach Intervention. Das mittlere Gesamtüberleben und das progressionsfreie Überleben waren jeweils 16,2 und 16,9 Monate ab Erstdiagnose und 8,3 und 6,8 Monate ab HIFU-Intervention. Schlussfolgerung Bei Patienten mit fortgeschrittenem Pankreaskarzinom führte HIFU zu einer signifikanten und anhaltenden Schmerzlinderung und Tumorvolumenreduktion im zeitlichen Verlauf unabhängig vom Metastasierungsstatus. Die Auswertung der Überlebensdaten gibt zusätzlich Hinweise auf einen potenziellen Vorteil. * contributed equally to this manuscript and share first co-authorship

23 January 2021 in European Radiology
Verified
Journal Article
Closed access
PDF file
MMMilka Marinova
Milka Marinova
HFHyuliya Feradova
Hyuliya Feradova
MGMaria A. Gonzalez-Carmona
Maria A. Gonzalez-Carmona
RCRupert Conrad
Rupert Conrad
TTTolga Tonguc
Tolga Tonguc
HSHolger M. Strunk
Holger M. Strunk

23 August 2021 in International Journal of Hyperthermia
Verified
Journal Article
Open access
MMMilka Marinova
Milka Marinova
SGShiwa Ghaei
Shiwa Ghaei
Florian Recker, MMEFlorian Recker, MME
Florian Recker, MME
TTTolga Tonguc
Tolga Tonguc
OKOlga Kaverina
Olga Kaverina
HSHolger Strunk
Holger Strunk
To evaluate treatment response of uterine fibroids after ultrasound guided high-intensity focused ultrasound (USgHIFU) with a special focus on fibroid size and characterization based on Funaki clas...

23 August 2021 in International Journal of Hyperthermia
Verified
Journal Article
Open access
TTTolga Tonguc
Tolga Tonguc
HSHolger Strunk
Holger Strunk
MGMaria A. Gonzalez-Carmona
Maria A. Gonzalez-Carmona
Florian Recker, MMEFlorian Recker, MME
Florian Recker, MME
DLDieter Lütjohann
Dieter Lütjohann
MMMilka Marinova
Milka Marinova
High-intensity focused ultrasound (HIFU) is an innovative noninvasive procedure for local ablation of different benign and malignant tumors. Preliminary data of animal studies suggest an ablation-a...

23 November 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Florian Recker, MMEFlorian Recker, MME
Florian Recker, MME
MTMarcus Thudium
Marcus Thudium
HSHolger Strunk
Holger Strunk
TTTolga Tonguc
Tolga Tonguc
SDSara Dohmen
Sara Dohmen
MMMilka Marinova
Milka Marinova
Little is known about the specific anaesthesiological and multidisciplinary management of high-intensity focused ultrasound (HIFU) in uterine fibroids. This observational single-center study is the first reporting on an interdisciplinary approach to optimize outcome following ultrasound (US)-guided HIFU in German-speaking countries. A sample of forty patients with symptomatic uterine fibroids was treated by HIFU. Relevant treatment parameters such as total treatment time for intervention, anaesthesia, and sonication time as well as total energy, body temperature, peri-interventional medication and complications were analyzed. Interventional variables did not correlate significantly either with opioid dose or with body temperature. The average fibroid volume reduction rate was 37.8% ± 23.5%, 48.5% ± 22.0% and 70.2% ± 25.5% after 3, 6 and 12 months, respectively. No major anaesthesiological complications occurred apart from an epileptic seizure prior to HIFU treatment in one patient. Peri-procedural hyperthermia (> 37.5 °C) occurred in two patients. Post-procedural two patients experienced a sciatic nerve irritation up to one year; one patient with very large treated fibroid experienced strong short-lasting post-procedural pain. There were two complication-free pregnancies of HIFU-treated patients. Multidisciplinary management is crucial to optimize safety and outcome of US-guided HIFU for uterine fibroids. Peri-procedural pain and temperature management are critical points where an adequate collaboration between anesthesiologist and interventionalist is mandatory.